109787 ⎘
dsDNA viruses; Details; Herpesviridae; Cytomegalovirus, e.g. human herpesvirus 5 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
PRE-FUSION-STABILIZED CMV GB PROTEIN NANOSTRUCTURES
#2PEPMIXES TO GENERATE MULTIVIRAL CTLS WITH BROAD SPECIFICITY
#3MODIFIED VIRUS-LIKE PARTICLES OF CMV
#4Use of Triplex CMV Vaccine in CAR T Cell Therapy
#5PROCESS FOR T CELL EXPANSION
#6BI-SPECIFIC TARGETED CHIMERIC ANTIGEN RECEPTOR T CELLS
#7VACCINE COMPOSITION
#8IMMUNOTHERAPEUTIC COMPOSITIONS FOR TREATMENT OF GLIOBLASTOMA MULTIFORME
#9CELL MEDIATED IMMUNE RESPONSE ASSAY
#10CYTOMEGALOVIRUS T CELL EPITOPES AND USES THEREOF
#11DUAL FUNCTION ANTIGEN BINDING MOLECULES
#12Human Cytomegalovirus Immunogenic Composition
#13HUMAN CYTOMEGALOVIRUS VACCINE
#14POXVIRUS-BASED VECTORS PRODUCED BY NATURAL OR SYNTHETIC DNA AND USES THEREOF
#15ANTIGEN DELIVERY PLATFORMS
#16IMMUNOGENIC COMPOSITIONS AND USES THEREOF
#17ENGINEERED FC DOMAINS AND ENGINEERED HCMV VIRAL FC RECEPTORS
#18MODIFIED HUMAN CYTOMEGALOVIRUS PROTEINS
#19A MURINE CYTOMEGALOVIRUS VACCINE VECTOR FOR ADMINISTRATION IN A NON-MOUSE SUBJECT
#20HUMAN CYTOMEGALOVIRUS RNA VACCINES
#21FCE MRNA CAPPING ENZYME COMPOSITIONS, METHODS AND KITS
#22MODIFIED CYTOMEGALOVIRUS PROTEINS AND STABILIZED COMPLEXES
#23PHARMACEUTICAL COMPOSITIONS FOR DELIVERY OF VIRAL ANTIGENS AND RELATED METHODS
#24NK CELLS EXHIBITING AN ADAPTIVE PHENOTYPE AND METHODS FOR PREPARING AND FOR USING
#25VACCINE COMPOSITIONS AND METHODS FOR ENHANCED ANTIGEN-SPECIFIC VACCINATION
#26VACCINE COMPOSITIONS OF HERPESVIRUS ENVELOPE PROTEIN COMBINATIONS TO INDUCE IMMUNE RESPONSE
#27SYNTHETIC DNA VACCINE IMMUNOGENIC IMPROVEMENTS
#28PEGYLATED LIPOSOMES FOR DELIVERY OF IMMUNOGEN-ENCODING RNA
#29BI-SPECIFIC TARGETED CHIMERIC ANTIGEN RECEPTOR T CELLS
#30HUMAN CYTOMEGALOVIRUS GB POLYPEPTIDE
#31T CELL RECEPTORS AND PEPTIDES DERIVED BY MUTATIONS FOR THE TREATMENT OF CANCER
#32T-CELL MODULATORY MULTIMERIC POLYPEPTIDES AND METHODS OF USE THEREOF
#33Use of Triplex CMV Vaccine in CAR T Cell Therapy
#34PEGYLATED LIPOSOMES FOR DELIVERY OF IMMUNOGEN-ENCODING RNA
#35CMV VECTORS AND USES THEREOF
#36FCE mRNA capping enzyme compositions, methods and kits
#37MVA vaccine for delivery of a UL128 complex and preventing CMV infection
#38Method of making lipid formulations with RNA encoding immunogens
#39Lipid formulations with RNA encoding immunogens
#40Immunisation with lipid formulations with RNA encoding immunogens
#41Antigen presenting scaffolds for immune-cell manipulation
#42GENETICALLY STABLE RECOMBINANT MODIFIED VACCINIA ANKARA (RMVA) VACCINES AND METHODS OF PREPARATION THEREOF
#43COMPOSITIONS AND METHODS FOR TREATMENT OF CYTOMEGALOVIRUS
#44MODIFIED CYTOMEGALOVIRUS PROTEINS AND STABILIZED COMPLEXES
#45Search-time field extraction in a data intake and query system
#46A METHOD TO GENERATE CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELLS (CAR-T CELLS) FROM PATHOGEN-SPECIFIC CYTOTOXIC LYMPHOCYTES TO ENABLE THE SUBSEQUENT IN VIVO MODULATION OF THEIR FUNCTIONAL ACTIVITY
#47METHODS AND VACCINES FOR INDUCING IMMUNE RESPONSES TO MULTIPLE DIFFERENT MHC MOLECULES
#48POXVIRUS-BASED VECTORS PRODUCED BY NATURAL OR SYNTHETIC DNA AND USES THEREOF
#49MULTIVIRUS-SPECIFIC T CELL IMMUNOTHERAPY
#50COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS TO IMMUNE CELLS
#51CELL-TARGETING MOLECULES COMPRISING SHIGA TOXIN A SUBUNIT EFFECTORS AND CD8+ T-CELL EPITOPES
#52Compositions, methods and kits for eliciting an immune response
#53Vaccine for eliciting immune response comprising RNA encoding an immunogen and lipid formulations comprising mole percentage of lipids
#54Vaccine for eliciting immune response comprising lipid formulations and RNA encoding multiple immunogens
#55T CELL EPITOPES OF HCMV AND USES OF THEREOF
#56ANTIGEN-SPECIFIC T CELL RECEPTORS AND T CELL EPITOPES
#57THIRD PARTY VIRUS-SPECIFIC T CELL COMPOSITIONS, AND METHODS OF MAKING AND USING THE SAME IN ANTI-VIRAL PROPHYLAXIS
#58ANTIGEN-SPECIFIC T CELL BANKS AND METHODS OF MAKING AND USING THE SAME THERAPEUTICALLY
#59Pepmixes to generate multiviral CTLS with broad specificity
#60FCE mRNA capping enzyme compositions, methods and kits
#61ANTIGEN DELIVERY PLATFORMS
#62INTRINSIC SYSTEM FOR VIRAL VECTOR TRANSGENE REGULATION
#63Methods of administering lipid formulations with viral immunogens
#64Methods of administering lipid formulations with immunogens
#65Lipid formulations with viral immunogens
#66Lipid formulations with immunogens
#67Antigen delivery platforms
#68COMPLEXES OF CYTOMEGALOVIRUS PROTEINS
#69Human cytomegalovirus vaccine
#70Human cytomegalovirus GB polypeptide
#71Human cytomegalovirus vaccine
#72Tetanus toxoid and CCL3 improve DC vaccines
#73Recombinant viral vector, immune composition containing same, and use thereof
#74Adoptive T-Cell Therapy for CMV Infection and CMV-Associated Diseases
#75BI-SPECIFIC TARGETED CHIMERIC ANTIGEN RECEPTOR T CELLS
#76Pepmixes to generate multiviral CTLs with broad specificity
#77Modified CMV gB protein and CMV vaccine including same
#78NK cells exhibiting an adaptive phenotype and methods for preparing and for using
#79Human herpesvirus immunotherapy
#80STABLE FORMULATIONS OF CYTOMEGALOVIRUS
#81IL-10 INHIBITION FOR VACCINES AND IMMUNOTHERAPY
#82Method of detecting new immunogenic T cell epitopes and isolating new antigen-specific T cell receptors by means of an MHC cell library
#83MULTIVIRUS-SPECIFIC T CELL IMMUNOTHERAPY
#84HCMV vaccine strain
#85Viral particle-based vaccine
#86MVA vaccine for delivery of a UL128 complex and preventing CMV infection
#87VACCINE COMPOSITIONS OF HERPESVIRUS ENVELOPE PROTEIN COMBINATIONS TO INDUCE IMMUNE RESPONSE
#88VACCINE COMPOSITION
#89CMV VECTORS AND USES THEREOF
#90Use of Triplex CMV Vaccine in CAR T Cell Therapy
#91VACCINE COMPOSITIONS AND METHODS FOR ENHANCED ANTIGEN-SPECIFIC VACCINATION
#92Genetically modified recombinant vaccinia ankara (RMVA) vaccines of improved stability and methods of preparation thereof
#93Compositions, methods and kits for eliciting an immune response
#94Compositions, methods and kits for eliciting an immune response
#95Self-asssembling nanostructure vaccines
#96Methods and compositions useful in generating non canonical CD8+ T cell responses
#97IMMUNOTHERAPEUTIC COMPOSITIONS FOR TREATMENT OF GLIOBLASTOMA MULTIFORME
#98CMV VECTORS COMPRISING MICRORNA RECOGNITION ELEMENTS
#99Compositions, methods and kits for eliciting an immune response
#100Human cytomegalovirus vaccine
#101Genetically stable recombinant modified vaccinia Ankara (rMVA) vaccines and methods of preparation thereof
#102AMINO ACID AND PEPTIDE CONJUGATES AND CONJUGATION PROCESS
#103Human cytomegalovirus RNA vaccines
#104Compositions, methods and kits for eliciting an immune response
#105Cytomegalovirus vectors eliciting T cells restricted by major histocompatibility complex E molecules
#106Pegylated liposomes for delivery of immunogen-encoding RNA
#107CMV-based intra-tumoral cancer therapies
#108MVA-gH/gL-PC vaccine derived antibodies neutralizing human cytomegalovirus infectivity and methods thereof
#109Cell mediated immune response assay
#110MVA vaccine for delivery of a UL128 complex and preventing CMV infection
#111Methods of treating CMV retinitis by T cell therapy
#112Generation and use in adoptive immunotherapy of stem cell-like memory T cells
#113Vaccine compositions of herpesvirus envelope protein combinations to induce immune response
#114Cytomegalovirus surface protein complex for use in vaccines and as a drug target
#115Human cytomegalovirus RNA vaccines
#116Antigen presenting scaffolds for immune-cell manipulation
#117Human cytomegalovirus vaccine
#118COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS TO IMMUNE CELLS
#119Re-directed immunotherapy
#120CMV vaccines
#121COMPLEXES OF CYTOMEGALOVIRUS PROTEINS
#122Antigen delivery platforms
#123Process for T cell expansion
#124Human cytomegalovirus gB polypeptide
#125MODULAR NANODEVICES FOR SMART ADAPTABLE VACCINES
#126Vaccine against beta-herpesvirus infection and use thereof
#127PEPTIDE PARTICLE FORMULATION
#128Recombinant HCMV and RHCMV vectors and uses thereof
#129Cationic oil-in-water emulsions
#130Antigen-specific T cell receptors and T cell epitopes
#131Long chain antigen containing interepitope sequence that promotes antigen presentation to T cells
#132Methods and vaccines for inducing immune responses to multiple different MHC molecules
#133Method for enrichment and expansion of virus antigen-specific T cells
#134MVA vaccine for delivery of a UL128 complex and preventing CMV infection
#135Adenine conjugate compounds and their use as vaccine adjuvants
#136Methods for detection of anti-cytomegalovirus neutralizing antibodies
#137Human cytomegalovirus RNA vaccines
#138Cytomegalovirus antigens
#139NK cells exhibiting an adaptive phenotype and methods for preparing and for using
#140Tetanus toxoid and CCL3 improve DC vaccines
#141BI-SPECIFIC TARGETED CHIMERIC ANTIGEN RECEPTOR T CELLS
#142Human herpesvirus immunotherapy
#143Pepmixes to generate multiviral CTLs with broad specificity
#144Compositions, methods and kits for eliciting an immune response
#145NOVEL CMV PP65 TARGETING DNA VACCINE FOR CANCER IMMUNOTHERAPY
#146Cytomegalovirus vectors eliciting T cells restricted by major histocompatibility complex E molecules
#147T cell receptors and peptides derived by mutations for the treatment of cancer
#148Method of detecting new immunogenic T cell epitopes and isolating new antigen-specific T cell receptors by means of an MHC cell library
#149METHOD OF ALTERING EXPRESSION OF ALTERNATIVE VIRAL GLYCOPROTEIN COMPLEXES
#150Human cytomegalovirus RNA vaccines
#151Method for preparing antigen-specific cytotoxic T-cells by using activated B-cells and use thereof
#152CMV ANTIGENS AND USES THEREOF
#153Cytomegalovirus antigens and uses thereof
#154Mammalian cells expressing cytomegalovirus antigens
#155CMV glycoproteins and recombinant vectors
#156Compositions and methods for treatment of cytomegalovirus
#157RECOMBINANT SELF-REPLICATING POLYCISTRONIC RNA MOLECULES
#158Complexes of cytomegalovirus proteins
#159Vaccine comprising beta-herpesvirus
#160Genetically stable recombinant modified vaccinia ankara (rMVA) vaccines and methods of preparation thereof
#161Cationic oil-in-water emulsions
#162Method for priming of T cells
#163CMV vectors comprising microRNA recognition elements
#164Methods of treating CMV retinitis by T cell therapy
#165HUMAN CYTOMEGALOVIRUS VACCINE COMPOSITIONS AND METHOD OF PRODUCING THE SAME
#166Amino acid and peptide conjugates and conjugation process
#167Vaccine compositions comprising a saponin adjuvant
#168Cytomegalovirus vaccines and methods of production
#169Peptide particle formulation
#170Human herpesvirus trimeric glycoprotein B, protein complexes comprising trimeric gB and their use as vaccines
#171CMV vaccines
#172Tetanus toxoid and CCL3 improve DC vaccines
#173CMV IMMUNO-STIMULATORY COMPOSITION
#174Targeting moiety peptide epitope complexes having a plurality of T-cell epitopes
#175CYTOMEGALOVIRUS-BASED IMMUNOGENIC PREPARATIONS
#176Compositions, methods and kits for eliciting an immune response
#177Complexes of cytomegalovirus proteins
#178Nucleic acid molecules encoding novel herpes antigens, vaccine comprising the same, and methods of use thereof
#179Recombinant HCMV and RHCMV vectors and uses thereof
#180Re-directed immunotherapy
#181DIRECTED IMMUNE STIMULATION
#182Compositions, methods, and kits for eliciting an immune response
#183Cell mediated immune response assay
#184MEANS AND METHODS FOR TREATING CMV
#185CONDITIONAL REPLICATING VIRAL VECTORS
#186Immunomodulatory peptides and methods of use thereof
#187VACCINE AGAINST BETA-HERPESVIRUS INFECTION AND USE THEREOF
#188Human herpesvirus immunotherapy
#189Re-directed immunotherapy
#190MVA vaccine for delivery of a UL128 complex and preventing CMV infection
#191Modular nanodevices for smart adaptable vaccines
#192Methods for detection of anti-cytomegalovirus neutralizing antibodies
#193PROCESS FOR T CELL EXPANSION
#194PEPMIXES TO GENERATE MULTIVIRAL CTLS WITH BROAD SPECIFICITY
#195Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalities
#196Compositions and methods for treatment of cytomegalovirus
#197CMV glycoproteins and recombinant vectors
#198Immunogenic compositions and uses thereof
#199Immunogenic combination compositions and uses thereof
#200Cationic oil-in-water emulsions
#201Conditional replicating cytomegalovirus as a vaccine for CMV
#202Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection
#203Production of dense bodies (DB) from HCMV-infected cells
#204Methods and compositions for cytomegalovirus IL-10 protein
#205Method for priming of T cells
#206Genetically stable recombinant modified vaccinia ankara (rMVA) vaccines and methods of preparation thereof
#207Nucleic acid molecules encoding novel herpes antigens, vaccine comprising the same, and methods of use thereof
#208Re-directed immunotherapy
#209Peptide scaffold design
#210Antigen-specific T cell receptors and T cell epitopes
#211Vaccine against beta-herpesvirus infection and use thereof
#212Small liposomes for delivery of immunogen encoding RNA
#213Virion-like delivery particles for self-replicating RNA molecules
#214Compositions, methods, and kits for eliciting an immune response
#215Recombinant HCMV and RHCMV vectors and uses thereof
#216COMPOSITION CONTAINING HCMV PARTICLES
#217COMPOSITION CONTAINING HCMV PARTICLES
#218Codon-optimized polynucleotide-based vaccines against human infection
#219CYTOMEGALOVIRUS-BASED IMMUNOGENIC PREPARATIONS
#220Compositions, methods, and kits for eliciting an immune response
#221Cytomegalovirus surface protein complex for use in vaccines and as a drug target
#222IMMUNOGENIC COMPOSITION COMPRISING PEPTIDES DERIVED FROM CYTOMEGALOVIRUS AND THE USE THEREOF
#223Influenza Vaccines, Antigens, Compositions, and Methods
#224Peptide particle formulation
#225MHC multimers in tuberculosis diagnostics, vaccine and therapeutics
#226Vaccine compositions comprising a saponin adjuvant
#227Cytomegalovirus surface protein complex for use in vaccines and as a drug target
#228Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection
#229Cytomegalovirus disintegrin-like peptides
#230COMPOSITION CONTAINING HCMV PARTICLES
#231Genetically stable recombinant modified vaccinia ankara (rMVA) vaccines and methods of preparation thereof
#232Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalities
#233Cytomegalovirus vaccines and methods of production
#234Vaccine for viruses that cause persistent or latent infections
#235RECOMBINANT VECTOR CONTAINING INFECTIOUS HUMAN CYTOMEGALOVIRUS GENOME WITH PRESERVED WILD-TYPE CHARACTERISTICS OF CLINICAL ISOLATES
#236Human Cytomegalovirus Latency Promoting Genes, Related Virus Variants and Methods of Use
#237CYTOMEGALOVIRUS PEPTIDES AND METHODS OF USE THEREOF
#238PROTEIN KINASE DEFICIENT, IMMUNOLOGICALLY ACTIVE CMVpp65 MUTANT CELLULAR VACCINES
#239Method of elicting or inducing an immune response
#240FUSION MULTIVIRAL CHIMERIC ANTIGEN
#241RECOMBINANT HUMAN CYTOMEGALOVIRUS AND VACCINES COMPRISING HETEROLOGOUS ANTIGENS
#242Direct vaccination of the bone marrow
#243VACCINE COMPOSITION FOR THE PREVENTION OF CMV INFECTION
#244Pharmaceutical compositions containing 1-methyl-D-tryptophan
#245Detection of primary infections with pathogens
#246Vaccine Compositions Comprising a Saponin Adjuvant
#247Siv and Hiv Vaccination Using Rhcmv- and Hcmv-Based Vaccine Vectors
#248Cytomegalovirus surface protein complex for use in vaccines and as a drug target
#249Cytomegalovirus vaccine
#250Vaccine composition
#251Human cytomegalovirus immunotherapy
#252Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection
#253Pharmaceutical Anti-Herpetic Composition, Method for Producing a Dosage Form Based Thereon and Method for the Use Thereof
#254Recombinant Human Cytomegalovirus And Vaccines Comprising Heterologous Antigens
#255Thermoreversible oil-in-water emulsion
#256Immuno-adjuvant emulsion
#257Peptides for vaccination against human CMV
#258Recombinant vector containing infectious human cytomegalovirus genome with preserved wild-type characteristics of clinical isolates
#259Protein kinase deficient, immunologically active CMVpp65 mutants
#260Dual antigen specific T cells with trafficking ability
#261Cytomegalovirus disintegrin-like peptides
#262CMV-IE1 peptides and method of use
#263Vaccine composition
#264Diagnostic reagents for human cytomegalovirus and methods of use
#265Transient expression of biologic materials